Market Overview:
The global genome-based drug market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicines, and technological advancements in genomics. Based on type, the genome-based drug market is segmented into insulin, growth hormone, monoclonal antibody (mAb), and other drugs. The insulin segment is expected to account for the largest share of the global genome-based drug market in 2018. This can be attributed to the high prevalence of diabetes mellitus across the globe. Based on application, hospital accounted for the largest share of the global genome-based drug market in 2017 and is projected to grow at a CAGR of 11% during forecast period 2018–2030 owing to increase in number of hospitals globally coupled with rising demand for personalized medicines.
Product Definition:
A genome-based drug is a type of medication that is designed to target specific genetic abnormalities within cancer cells. These medications are typically more effective and cause fewer side effects than traditional chemotherapy drugs. The importance of genome-based drugs lies in their ability to specifically target cancer cells, thus reducing the potential for damage to healthy cells.
Insulin:
Insulin is a hormone, which facilitates the entry of glucose into the blood cells. Insulin opens up the cellular door for sugar to enter in response to an increase in blood sugar levels. The primary functions of insulin are to enable glucose uptake by muscle and liver tissue and help maintain normal blood sugar levels in humans.
Insulin also has other functions such as facilitating fat storage (in case of negative energy balance) or helping fats get converted into energy (if there is too much dietary fat).
Growth Hormone:
Growth hormone (GH) is a peptide hormone that controls the growth and development of the body. It plays an important role in maintaining optimal health during childhood as well as during adulthood. Growth hormone deficiency is associated with several diseases and disorders including short bowel syndrome, Prader-Willi syndrome, pituitary tumors,growth-hormone releasing factor deficiency or resistance, gigantism (in adolescents), Cushing's syndrome etc.
Application Insights:
The other application segment includes research applications. The growing adoption of genome-based therapies has led to an increase in the number of clinical trials. This, in turn, is expected to boost the demand for sequencing over the forecast period.
Genome-based drugs find their major use in hospital settings as they reduce mortality and morbidity associated with diseases by identifying genetic mutations responsible for causing these conditions early during its progression. These factors are anticipated to drive this segment over the forecast period owing to rising healthcare costs along with a growing preference towards preventative medicine that targets common gene variants responsible for causing rare diseases or complex disorders that occur frequently among several individuals within a population (i.e., familial disease).
Pharmaceutical factories are another significant application area where genomics plays an important role as it involves production of biopharmaceuticals such as monoclonal antibodies.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of genome-based drug manufacturers and distributors, availability of advanced healthcare facilities, high adoption rate for novel treatment options, and favorable reimbursement policies & regulatory reforms. The U.S., which is at the forefront in North America with a revenue share of over 80% in 2017 is also one of the top countries globally that have adopted this technology most aggressively (in terms of usage).
Asia Pacific region is expected to witness lucrative growth during the forecast period owing to rising disposable income levels coupled with growing awareness about genomic medicine among patients; increasing investment by private companies as well as public agencies for developing new drugs based on genome; improving healthcare infrastructure especially due to government initiatives such as “Hospital EHR†program by USAID/PEPFAR; and other socio-economic factors that are driving regional growth.
Growth Factors:
- Increasing demand for personalized medicines
- Advances in genomic sequencing technology and data analysis
- Growing investment in genomics research by pharmaceutical and biotechnology companies
- Proliferation of genome-based diagnostics tests
- Emergence of precision medicine
Scope Of The Report
Report Attributes
Report Details
Report Title
Genome-Based Drug Market Research Report
By Type
Insulin, Growth Hormone, Monoclonal Antibody, Other
By Application
Hospital, Pharmaceutical Factory, Other
By Companies
Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, Biocon, Reliance Life Sciences, Probiomed, Biosidus, AMEGA Biotech, Celltrion, LG Life Science, Dong-A Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Genome-Based Drug Market Report Segments:
The global Genome-Based Drug market is segmented on the basis of:
Types
Insulin, Growth Hormone, Monoclonal Antibody, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmaceutical Factory, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sandoz International
- Teva pharmaceutical industries
- Mylan
- 3SBio
- Shanghai Fosun Pharmaceutical
- Tonghua Dongbao Pharmaceutical
- Biocon
- Reliance Life Sciences
- Probiomed
- Biosidus
- AMEGA Biotech
- Celltrion
- LG Life Science
- Dong-A Pharmaceutical
Highlights of The Genome-Based Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin
- Growth Hormone
- Monoclonal Antibody
- Other
- By Application:
- Hospital
- Pharmaceutical Factory
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genome-Based Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Genome-based drug is a type of drug that is based on the genetic code of a particular organism. This means that the drug will target specific genes in the organism and may have different effects depending on which genes are targeted.
Some of the major companies in the genome-based drug market are Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, Biocon, Reliance Life Sciences, Probiomed, Biosidus, AMEGA Biotech, Celltrion, LG Life Science, Dong-A Pharmaceutical.
The genome-based drug market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genome-Based Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genome-Based Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genome-Based Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genome-Based Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genome-Based Drug Market Size & Forecast, 2020-2028
4.5.1 Genome-Based Drug Market Size and Y-o-Y Growth
4.5.2 Genome-Based Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Insulin
5.2.2 Growth Hormone
5.2.3 Monoclonal Antibody
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmaceutical Factory
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Genome-Based Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Genome-Based Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Insulin
9.6.2 Growth Hormone
9.6.3 Monoclonal Antibody
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmaceutical Factory
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Insulin
10.6.2 Growth Hormone
10.6.3 Monoclonal Antibody
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmaceutical Factory
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Insulin
11.6.2 Growth Hormone
11.6.3 Monoclonal Antibody
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmaceutical Factory
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Insulin
12.6.2 Growth Hormone
12.6.3 Monoclonal Antibody
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmaceutical Factory
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Insulin
13.6.2 Growth Hormone
13.6.3 Monoclonal Antibody
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmaceutical Factory
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Genome-Based Drug Market: Competitive Dashboard
14.2 Global Genome-Based Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sandoz International
14.3.2 Teva pharmaceutical industries
14.3.3 Mylan
14.3.4 3SBio
14.3.5 Shanghai Fosun Pharmaceutical
14.3.6 Tonghua Dongbao Pharmaceutical
14.3.7 Biocon
14.3.8 Reliance Life Sciences
14.3.9 Probiomed
14.3.10 Biosidus
14.3.11 AMEGA Biotech
14.3.12 Celltrion
14.3.13 LG Life Science
14.3.14 Dong-A Pharmaceutical
